| Name | Platelet-activating factor receptor | ||
| UniProt ID | PTAFR_HUMAN | ||
| Gene Name | PTAFR | ||
| Gene ID | 5724 | ||
| Synonyms |
PTAFR, PAFR
|
||
| Sequence |
MEPHDSSHMDSEFRYTLFPIVYSIIFVLGVIANGYVLWVFARLYPCKKFNEIKIFMVNLT
MADMLFLITLPLWIVYYQNQGNWILPKFLCNVAGCLFFINTYCSVAFLGVITYNRFQAVT RPIKTAQANTRKRGISLSLVIWVAIVGAASYFLILDSTNTVPDSAGSGNVTRCFEHYEKG SVPVLIIHIFIVFSFFLVFLIILFCNLVIIRTLLMQPVQQQRNAEVKRRALWMVCTVLAV FIICFVPHHVVQLPWTLAELGFQDSKFHQAINDAHQVTLCLLSTNCVLDPVIYCFLTKKF RKHLTEKFYSMRSSRKCSRATTDTVTEVVVPFNQIPGNSLKN |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 9.A.14.13.3 | ||
| KEGG ID | hsa5724 | ||
| TTD ID | T87023 | ||
| Pfam | PF00001; PF03530; PF03600; PF10516 | ||
| Pair Name | Ginkgolide B, Cisplatin | |||
| Phytochemical | Ginkgolide B | |||
| Drug | Cisplatin | |||
| Disease Info | [ICD-11: 2B66.Z] | Oral cancer | Investigative | |
| Regulate Info | Down-regulation | Platelet-activating factor receptor | Expression | |
| Result | These results suggest that PAFR is a therapeutic target for modulating CDDP sensitivity in OSCC cells. Thus, GB may be a novel drug that could enhance combination chemotherapy with CDDP for OSCC patients. | |||
